AKT1 and melanoma: Our findings verified that ABZ treatment suppresses the EMT of melanoma in vitro and in vivo by inhibiting the AKT/GSK-3β pathway, resulting in decreased pGSK-3β/Ser9 (inactive form of GSK-3β) expression.